Abstract
Natural killer cells can discriminate between normal cells and cells that do not express adequate amounts of major histocompatibility complex (MHC) class I molecules. The discovery, both in mouse and in human, of MHC-specific inhibitory receptors clarified the molecular basis of this important NK cell function. However, the triggering receptors responsible for positive NK cell stimulation remained elusive until recently. Some of these receptors have now been identified in humans, thus shedding some light on the molecular mechanisms involved in NK cell activation during the process of natural cytotoxicity. Three novel, NK-specific, triggering surface molecules (NKp46, NKp30, and NKp44) have been identified. They represent the first members of a novel emerging group of receptors collectively termed natural cytotoxicity receptors (NCR). Monoclonal antibodies (mAbs) to NCR block to differing extents the NK-mediated lysis of various tumors. Moreover, lysis of certain tumors can be virtually abrogated by the simultaneous masking of the three NCRs. There is a coordinated surface expression of the three NCRs, their surface density varying in different individuals and also in the NK cells isolated from a given individual. A direct correlation exists between the surface density of NCR and the ability of NK cells to kill various tumors. NKp46 is the only NCR involved in human NK-mediated killing of murine target cells. Accordingly, a homologue of NKp46 has been detected in mouse. Molecular cloning of NCR revealed novel members of the Ig superfamily displaying a low degree of similarity to each other and to known human molecules. NCRs are coupled to different signal transducing adaptor proteins, including CD3ζ, Fc∍RIγ, and KARAP/DAP12. Another triggering NK receptor is NKG2D. It appears to play either a complementary or a synergistic role with NCRs. Thus, the triggering of NK cells in the process of tumor cell lysis may often depend on the concerted action of NCR and NKG2D. In some instances, however, it may uniquely depend upon the activity of NCR or NKG2D only. Strict NKG2D-dependency can be appreciated using clones that, in spite of their NCRdullphenotype, efficiently lyse certain epithelial tumors or leukemic cell lines. Other triggering surface molecules including 2B4 and the novel NKp80 appear to function as coreceptors rather than as true receptors. Indeed, they can induce natural cytotoxicity only when co-engaged with a triggering receptor. While an altered expression or function of NCR or NKG2D is being explored as a possible cause of immunological disorders, 2B4 dysfunction has already been associated with a severe form of immunodeficiency. Indeed, in patients with the X-linked lymphoproliferative disease, the inability to control Epstein-Barr virus infections may be consequent to a major dysfunction of 2B4 that exerts inhibitory instead of activating functions.
References
127
Referenced
1,408
10.1146/annurev.immunol.14.1.619
10.1146/annurev.immunol.16.1.359
10.1146/annurev.immunol.17.1.875
10.1016/S0065-2776(08)60019-X
10.1006/smim.2000.0216
10.1002/eji.1830250210
10.1016/S1074-7613(00)80530-0
10.1002/(SICI)1521-4141(199910)29:10<3148::AID-IMMU3148>3.0.CO;2-L
10.1084/jem.190.6.793
10.1073/pnas.93.22.12433
10.1016/S0167-5699(97)01236-X
10.1016/S0167-5699(96)10075-X
10.1046/j.1525-1438.1996.06010001.x
10.1126/science.280.5361.248
10.1016/S0952-7915(97)80155-0
10.1182/blood.V90.6.2390
10.1016/S1074-7613(00)80065-5
10.1016/0167-5699(90)90097-S
10.1111/j.1600-065X.1997.tb00943.x
10.1016/0167-5699(92)90042-6
10.1016/0092-8674(92)90029-C
10.1016/0092-8674(92)90030-G
10.1002/eji.1830240434
10.1074/jbc.272.14.8989
10.1016/S0167-5699(00)01596-6
10.1038/317428a0
10.4049/jimmunol.136.11.3939
/ J. Immunol. by Bolhuis RL (1986)10.1111/j.1600-065X.1997.tb00947.x
10.1016/S1074-7613(00)70060-4
10.1016/S0198-8859(99)00162-7
10.1084/jem.186.7.1129
10.1084/jem.188.5.953
10.1038/338383b0
10.1016/0167-5699(95)80105-7
10.1038/347189a0
10.1038/342803a0
10.1084/jem.175.5.1381
10.1146/annurev.immunol.15.1.203
10.1146/annurev.iy.09.040191.002325
10.1074/jbc.270.27.16415
10.1084/jem.177.5.1475
10.1084/jem.186.12.1965
10.1002/eji.1830241035
10.1002/eji.1830231017
10.1073/pnas.080588597
10.1002/(SICI)1521-4141(199903)29:03<1014::AID-IMMU1014>3.0.CO;2-O
10.1016/S0165-2478(99)00052-8
10.1016/S1074-7613(00)00035-2
10.1084/jem.190.10.1505
10.4049/jimmunol.162.8.4745
/ J. Immunol. by Neville MJ (1999)10.1084/jem.187.12.2065
10.4049/jimmunol.138.4.1297
/ J. Immunol. by Ferrini S (1987)10.1146/annurev.iy.04.040186.003341
10.1084/jem.189.5.787
10.4049/jimmunol.158.11.5083
/ J. Immunol. by Olcese L (1997)10.1038/35642
10.1002/(SICI)1521-4141(199802)28:02<599::AID-IMMU599>3.0.CO;2-F
10.1016/S1074-7613(00)80574-9
10.1084/jem.191.8.1259
10.1002/1521-4141(200012)30:12<3569::AID-IMMU3569>3.0.CO;2-E
10.1002/(SICI)1521-4141(199905)29:05<1656::AID-IMMU1656>3.0.CO;2-1
10.1146/annurev.immunol.16.1.433
10.1111/j.1399-3089.1996.tb00133.x
10.1111/j.1399-3089.1996.tb00137.x
10.4049/jimmunol.149.4.1416
/ J. Immunol. by Inverardi L (1992)10.1097/00007890-199601150-00023
10.1084/jem.173.4.1017
10.1002/eji.1830270230
10.4049/jimmunol.157.11.4741
/ J. Immunol. by Lazetic S (1996)10.1002/(SICI)1521-4141(199801)28:01<327::AID-IMMU327>3.0.CO;2-O
10.1002/eji.1830271114
10.1038/35869
10.1084/jem.187.5.813
10.1073/pnas.95.9.5199
10.1126/science.285.5428.730
10.4049/jimmunol.163.9.4651
/ J. Immunol. by Chang C (1999)10.1126/science.285.5428.727
10.1073/pnas.93.22.12445
10.1073/pnas.96.12.6879
- Pende D, Cantoni C, Vitale M, Rivera P, Castriconi R, Marcenaro S, Nahni M, Biassoni R, Bottino C, Moretta A, Moretta L. 2000. Involvement of NKG2D in the tumor cell by normal NK cells: complementary role with NKp46, NKp44 and NKp30 natural cytotoxicity receptors. Submitted
10.1073/pnas.95.11.6320
10.1038/77793
10.1016/S1074-7613(00)80222-8
10.4049/jimmunol.161.7.3501
/ J. Immunol. by Malarkannan S (1998)10.1093/oxfordjournals.jbchem.a021517
{'key': 'b86', 'first-page': 'A1018', 'volume': '14', 'author': 'Cosman D', 'year': '2000', 'journal-title': 'Faseb J.'}
/ Faseb J. by Cosman D (2000){'key': 'b87', 'first-page': 'A1018', 'volume': '14', 'author': 'Chalupny J', 'year': '2000', 'journal-title': 'Faseb J.'}
/ Faseb J. by Chalupny J (2000)10.4049/jimmunol.151.1.60
/ J. Immunol. by Garni-Wagner BA (1993)10.1002/eji.1830250440
10.4049/jimmunol.151.10.5328
/ J. Immunol. by Mathew PA (1993)10.1016/0167-5699(96)80617-7
10.1084/jem.188.11.2083
10.4049/jimmunol.161.11.5809
/ J. Immunol. by Latchman Y (1998){'key': 'b94', 'first-page': '6', 'volume': '7', 'author': 'Moretta A', 'year': '1992', 'journal-title': 'Int. J. Cancer.'}
/ Int. J. Cancer. by Moretta A (1992)10.1084/jem.178.4.1397
10.1034/j.1399-0039.1999.540103.x
10.1002/(SICI)1521-4141(199911)29:11<3466::AID-IMMU3466>3.0.CO;2-9
10.1002/(SICI)1521-4141(199905)29:05<1676::AID-IMMU1676>3.0.CO;2-Y
10.4049/jimmunol.162.12.6981
/ J. Immunol. by Tangye SG (1999)10.1002/1521-4141(200003)30:3<787::AID-IMMU787>3.0.CO;2-I
10.1084/jem.192.3.337
10.1073/pnas.95.23.13765
10.1038/2424
10.1038/26683
10.1002/1521-4141(200012)30:12<3718::AID-IMMU3718>3.0.CO;2-I
10.1016/S0092-8674(00)80901-0
10.4049/jimmunol.162.5.2453
/ J. Immunol. by Jevremovic D (1999){'key': 'b108', 'author': 'Vitale M', 'year': '2000', 'journal-title': 'Eur. J. Immunol.'}
/ Eur. J. Immunol. by Vitale M (2000)10.1002/1521-4141(200002)30:2<568::AID-IMMU568>3.0.CO;2-Y
10.1084/jem.171.3.695
10.1084/jem.172.6.1589
10.1084/jem.178.2.597
10.1084/jem.182.3.875
10.1002/eji.1830260823
10.1084/jem.183.2.645
10.1002/eji.1830271203
10.1016/S1074-7613(00)80426-4
10.1016/S1074-7613(00)00034-0
10.1084/jem.191.8.1341
10.1084/jem.187.7.1093
10.1126/science.7517574
10.1084/jem.187.1.117
10.1016/S0165-2478(97)00072-2
{'key': 'b124', 'first-page': '736', 'volume': '201', 'author': 'Purtilo DT', 'year': '1974', 'journal-title': 'N. Engl. J. Med.'}
/ N. Engl. J. Med. by Purtilo DT (1974)10.1203/00006450-199510000-00001
{'key': 'b126', 'first-page': '325', 'volume': '1', 'author': 'Sullivan Jl', 'year': '1989', 'journal-title': 'Immunodef. Rev.'}
/ Immunodef. Rev. by Sullivan Jl (1989)10.1038/376260a0
Dates
Type | When |
---|---|
Created | 23 years ago (July 27, 2002, 7:40 a.m.) |
Deposited | 2 years, 4 months ago (April 23, 2023, 2:20 p.m.) |
Indexed | 3 days, 9 hours ago (Aug. 23, 2025, 12:59 a.m.) |
Issued | 24 years, 4 months ago (April 1, 2001) |
Published | 24 years, 4 months ago (April 1, 2001) |
Published Print | 24 years, 4 months ago (April 1, 2001) |
@article{Moretta_2001, title={Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis}, volume={19}, ISSN={1545-3278}, url={http://dx.doi.org/10.1146/annurev.immunol.19.1.197}, DOI={10.1146/annurev.immunol.19.1.197}, number={1}, journal={Annual Review of Immunology}, publisher={Annual Reviews}, author={Moretta, Alessandro and Bottino, Cristina and Vitale, Massimo and Pende, Daniela and Cantoni, Claudia and Mingari, Maria Cristina and Biassoni, Roberto and Moretta, Lorenzo}, year={2001}, month=apr, pages={197–223} }